Original Article

Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?

Jamshid Salamzadeh^a, Naghmeh Foroutan^{a*}, Hamid Reza Jamshidi^a, Hamid Reza Rasekh^a, Ali Rajabzadeh Ghatari^b, Arash Foroutan^c and Mohsen Nafar^d

^aDepartment of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ^bTarbiat Modares University. ^cSchool of Pharmacy, Tehran University of Medical Sciences. ^dDepartment of Kidney Transplantation, Urology Nephrology Research Center (UNRC), Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

The primary aim of the study was to estimate costs of treatment for the first year after renal transplantation from the perspective of health insurance organizations in Iran.

An Excel-based and a Monte Carlo model were developed to determine the treatment costs of current clinical practice in renal transplantation therapy (RTT). Inputs were derived from Ministry of Health and insurance organizations database, hospital and pharmacy records, clinical trials and local and international literature. According to the model, there were almost 17,000 patients receiving RTT in Iran, out of which about 2,200 patients underwent the operation within the study year (2011 - 2012; n = 2,200).

The estimated first year total treatment cost after renal transplantation was almost \$14,000,000. These costs corresponded to annual total cost per patient of almost \$6500 for the payers.

Renal transplantation therapy is almost fully reimbursed by government in Iran. However, regarding new expensive medicines, cost of medical expenditure is rapidly growing and becoming quite unaffordable for the government; therefore, out-of-pocket (OOP) payments are dramatically increasing over time. In order to improve reimbursement policy making under pressure of current budget constraints, the present study is providing decision makers with practical tools make it possible for them to easily compare budgetary impact of the current therapy strategy with the future financial consequences of purchasing newly proposed medicines. In other words having estimation of the current budget spending on RTT would help policy makers in making efficient resource allocation and decrease quite high OOP expenditures.

Keywords: Cost; Renal transplantation therapy; Insurance; Policy making; Budget.

Introduction

The number of patients with end-stage renal disease (ESRD) is increasing worldwide at a rate of almost 7% to 8% per year (1). Renal transplantation therapy (RTT) has been considered a cost-effective alternative therapy compare to other renal replacement therapies (RRT) such as hemodialysis or peritoneal dialysis in patients suffering from end-stage renal disease (ESRD) (2) Prevalence and incidence of ESRD in Iran is almost 357 per million population (pmp) and 66 pmp, respectively (3, 4). From March

^{*} Corresponding author:

E-mail: nforoutan88@gmail.com

2011 to March 2012, there were almost 17,000 patients receiving RTT in Iran, out of which about 2,200 patients had renal transplantation.

In recent years, because of economic crises, policy makers have faced much more difficulties in allocating limited available budget to several diseases. Notwithstanding renal replacement therapies (RRT) - transplantation and hemodialysis-have been grouped as special diseases and receive subsidy along with full reimbursement coverage in Iran, out-of-pocket (OOP) expenditure is considerable regarding both of the mentioned therapies.

Renal transplantation (RT) has a quite long history in Iran. The first surgery in the Middle East region was performed in 1967 in Shiraz, south of Iran. Since then, the number of candidate patients for receiving renal transplantation increased; however, dialysis was still the treatment of choice due to the fact that patients used to go to European countries for the transplantation procedure with a public fund; thus, it was costly for Ministry of Health and also there was a long transplant waiting list for patients. Finally, in 1985, the government decided to provide patients with renal transplantation operation inside the country (5, 6).

Considering Article 29 of Iranian Constitution, according to which accessibility and affordability of health services for the entire population are a policy focus of the Iranian Government (7) there are special facilities and reimbursement processes provided by Ministry of Health and insurance organizations which make RTT and dialysis more affordable and also accessible for eligible patients from different socioeconomic status. There are several governmental and quasi-government organizations engaged in ESRD issue: a) Ministry of Health (MOH) as the main sponsor, b) Social Security Organization (SSO), c) Medical Service Insurance Organization (MSIO), d) Armed Forces Medical Service Organization (AFMSO), e) Imam Khomeini Relief Foundation (IKRF), and f) Special Organizations such as Ministry of Welfare and Social Security, oil companies, radio and television broadcasters, banks and non-governmental organizations (NGOs) (7, 8).

Nowadays, regarding new expensive medicines and interventions, cost of RRT medical

expenditure is rapidly growing and becoming quite unaffordable for the government; therefore, OOP payments are dramatically increasing over time.

In order to improve reimbursement decision making under pressure of current budget constraints, there is an essential need to provide insurance policy makers with effective financial budgeting tools and thus allocate the budget in a way that the trade-off between effectiveness and staying within the budget is always sustained in terms of therapeutic guidelines.

In the present study, current treatment cost of renal transplantation therapy was calculated for Iranian insurance organizations in order to provide them with practical tools, make it possible for them to have an estimation of financial impact of current practice in RTT, especially in comparison with other RRTs (mainly hemodialysis), and also provide them with the chance of simply calculating budgetary impact of purchasing newly introduced costeffective medicines in RTT to be provided with satisfactory insurance coverage in the future.

Experimental

Estimates of patient population and data sources .Population-based incidence data were obtained from a central registry system in the Management Center for Transplantation and Special Diseases (MCTSD), affiliated to Ministry of Health (MOH) (9). Prevalence data were not considered in this study. Tariffs and expenditure data of RTT and dialysis were extracted from insurance organizations` database. Regarding required probabilities, hospital-based registries, local clinical trials and national and international literature were reviewed.

Clinical data were obtained on the following key events: initial hospitalization for transplantation, immunosuppressive drug use, graft failure, acute rejection, delayed graft function, cytomegalovirus (CMV) infection and other important adverse events' treatment.

Estimates on in-patient drug use, treatment duration and rate of rehospitalization were based on local standard protocol for RTT and dialysis, SSO and MSIO databases and hospital-based registries. Estimates on out-patient details of

Maintenance Therapy	Dosage form	Dosage/day/ patient	Unit price (IRR)	Total cost/day / patient (IRR)	Nr. of Eligible patients	Duration (D.)	Total cost (IRR)	Total cost (\$USD)
Cyclosporine (Generic)	Cap: 25, 100 ,50 mg	$150^{\dagger} \mathrm{mg} \mathrm{qd}$	300, 1200, 1500	5,167,800 [‡]	-	365	1,886,247,000	153,854
MycophenolateMofetil	Cap: 500 mg	2 g qd	11,000	44,000	2,200	365	35,332,000,000	2,881,892
Prednisolone	Tab: 5 mg	5mg/d qd	130	130	2,200	365	104,390,000	8,515
Tacrolimus	Tab: 0.5 mg	0.2mg/Kg/d	1,000	28,000	220 [§]	365	2,248,400,000	183,393
Total cost							39,571,037,000	3,227,654

Table 1. Cost of maintenance therapy (immune suppressive agents) according to tariffs as unit price in both IRR and USD (2011-2012).

D.= day; qd= once per day, everyday

† Almost 60% (more than half) of the patients receiving 150 mg/day qd. The rest, are using 100 mg (5%), 125 mg (10%), 175 mg (10%), 200 mg (10%) and 225 mg (5%) per day (Source: insurance organizations database).

‡Total cost-patient has been calculated based on proportion of patients using different dosages. Number of patients using Tacrolimus has been excluded.

§In average 10% of patients have their second or more transplantation and use Tacrolimus.

the immune suppressive regimen were obtained from Helal -e- Ahmar pharmacy records and SSO database.

According to MCTSD and database of insurance organizations, during the study year (2011- 2012), almost 17,000 patients were receiving RTT, out of which about 2,200 patients (aged between 18-70 years old) had their transplantation operation. There are two main semi-public hospitals in Tehran (capital city) performing renal transplantation which are in charge of almost half of the operations in the country (25% Baghiatollah Hospital and 25% Shahid Labbafinejad Teaching Hospitals).

Cost of initial hospitalization for transplantation

There is a global fixed tariff (GT) for transplantation provided by insurance organizations in both public and private hospitals with no co-payment or franchise for patients (except 10% for hospitalization in some hospitals). According to tariffs in the study year, a fixed amount of almost 39,000,000 IRR (\$3,181US) was paid for each pair of operation (recipient and donor) for the whole hospitalization period (5 to 30 days). Total tariff was defined as 650 K, in which K was almost 60,000 IRR in the study year. Some drugs (e.g. ganciclovir) are not included in the GF. In some cases, real costs become greater than the compensation and patients should pay the difference as OOP. Considering the average annual number of patients having renal transplantation (2,200 patients), the total budget spent for initial hospitalization for transplantation was almost 86 billion IRR (\$7,000,000).

Cost of immune suppressive agents

Regarding maintenance therapy (MT) in RTT, the most costly and important immunosuppressive drugs are cyclosporine (CsA), mycophenolate mofetile (MMF) (10), sirolimus (SRL) and tacrolimus. The mean CsA dose is 150 mg/d per patient and is available in three dosages (25, 50, 100 mg oral tablets); only the generic form is included in the insurers' formulary. The CsA cost was acquired from database of insurance organizations and calculated based on proportion of patients normally using different dosages (based on pharmacy records). Tacrolimous was usually used in patients who had their second or more transplantation (almost 10%) and the rest (90%) used CsA as the main immune surpressive agent. Rapamune® (SRL) was only administered in special cases (less than 1%); however, it was not included in the analysis due to the fact that, over the study year, it did not have any insurance coverage (Table 1).

Cost of adverse events (AE) treatment major adverse events related to CsA-based regimens during 12 months posttransplantation are mainly acute rejection (18%) (4), delayed graft function (17%) (11), CMV infection (21%), graft failure (10.5%), thrombocytopenia (8%), hyperlipidemia (14%) (12) and hypertension (67%) (13-17) Cost of each adverse event per patient and total cost of

Adverse Events/ Treatment	Dosage form	Dosage/day/ patient	Nr. per day	Duration (D.)	Unit price (IRR)	Total cost / patient (IRR)	Total cost (\$US)
CMV				(21)	(1111)	Puulun (1111)	(\$00)
Ganciclovir	For inj: 500mg	For treatment: 5 mg/Kg q 12 hr until treatment	2	7	250,000	3,500,000	285
Hospitalization				7	1,600,000	11,200,000	914
Acute Rejection							
Methylprednisolone	For inj: 500 mg	250-1000 mg	1	7	200,000	1,400,000	114
ATG	Inj: 250mg/5mL	10-20mg/Kg	4	7	550,000	15,400,000	1,256
Gancyclovir	For inj: 500mg	For prophylaxy: 5 mg/Kg q 24 hr until hospitalization	1	7	250,000	1,750,000	143
Hospitalization				7	1,600,000	11,200,000	914
Graft Failure							
Dialysis				10 times	743,200	7,432,000	606
Re- transplantation					650K§	39,000,000	3,181
Delayed Graft Function							
ATG	Inj: 250mg/5mL	10-20mg/Kg	4	10	550,000	22,000,000	1,794
Gancyclovir	For inj: 500mg	For prophylaxy: 5 mg/Kg q 24 hr until hospitalization	1	10	250,000	2,500,000	204
Dialysis				3 times	743,200	2,229,600	182
Infections							
Co-trimoxsazole	Tab: 400/80mg	q.d. –b.i.d.	2	180	210	75,600	6
Cefazoline	For Inj: 1g	3g	3	2	6,000	36,000	3
Nystatin	Tab: 500,000 U	t.i.d- q.i.d.	4	180	450	324,000	26
Fluconazole	Tab: 100mg	100 mg	1	180	1,200	216,000	18
Hyperlipidemia							
Atorvastatin	Tab: 10, 20, 40 mg	10-40 mg	1	365	1,100	401,500	33
Hypertension							
Amlodipin	Tab: 5 mg	5-10 mg	1	365	150	54,750	4
Thrombocytopenia							
Plasmapheresis			-	10 times	1,300,000	13,000,000	1,060
Total						131,719,450	10,744

Table 2.Cost of adverse events	per patient in RT	T using tariffs as unit	price.Total cost values are	in IRR and USD, Iran ((2011-2012).
--------------------------------	-------------------	-------------------------	-----------------------------	------------------------	--------------

CMV = cytomegalovirus; ATG = Antithymocyte globulin; hr = hour; b.i.d.= twice per day; t.i.d.= three times per day; q.i.d.= four times per day; q.d. = once per day, every day. \$K: 60,000 IRR.

Adverse Events	Probability	Unit cost per patient (IRR)*	Prob. × Unit cost / patient	Total cost (IRR) $(n = 2,200)$	Total Cost (\$US)
CMV	0.21	14,700,000	3,087,000	6,791,400,000	553,948
Other Infections	1**	651,600	651,600	1,433,520,000	116,927
Delayed Graft Function	0.17	26,729,600	4,544,032	9,996,870,400	815,405
Acute Rejection	0.18	29,750,000	5,355,000	11,781,000,000	960,930
Hyperlipidemia	0.14	401,500	56,210	123,662,000	10,087
Hypertension	0.67	54,750	36,683	80,701,500	6,583
Graft Failure	0.105	46,432,000	4,875,360	10,725,792,000	874,861
Thrombocytopenia	0.08	13,000,000	1,040,000	2,288,000,000	186,623
Total cost			19,645,885	43,220,945,900	3,525,363

*For each adverse event, unit cost per patient has been calculated in Table 2.

**Probability equal to 1 means that the medication has been considered for all patient population (100%, n = 2, 200).

 Table 4. Total cost of miscellaneous medicinesas posttrans plantation medication according to local standard guidelines in RTT, Iran (2011-2012).

Miscellaneous medicines	Dosage form	Dosage/ patient	Nr. per day	Duration (D.)	Unit price (IRR)	Total cost / patient (IRR)	Nr. of eligible patients	Total cost (IRR)	Total cost (\$US)
Calcitriol (Rocaltrol®)	Cap: 0.25 mcg	q.d.	1	365	2300	839,500	2,200	1,846,900,000	150,644
Ferrus Sulphate	Tab: 50 mg	q.d.	1	365	55	20,075	2,200	44,165,000	3,602
A.S.A	Tab: 80 mg	q.d.	1	365	83	30,295	2,200	66,649,000	5,436
Ranitidine	Tab: 150 mg	h.s.	1	365	55	20,075	2,200	44,165,000	3,602
Calcium Carbonate	Tab: 500 mg	q.d.	1	365	155	56,575	2,200	124,465,000	10,152
Total Cost								2,126,344,000	173,438

D. = day; A.S.A= acetylsalicylic acid, Aspirin; q.d. = everyday, once per day; h.s. = at bed time.

adverse events are summarized in Tables 2 and 3.

Regarding CMV infection, ganciclovir was administered over a 7-day hospitalization with an average treatment dose of 5 mg/Kg every 12 hours. In the case of acute rejection episodes, Methylprednisolone (daily boluses of 250-1000 mg), antithymocyte globulin (ATG) with a daily dose of 10- 20 mg/Kg and ganciclovir for CMV infection prophylaxis (5 mg/Kg every 24 hour over hospitalization duration) are administered in renal transplant recipients. ATG with quite similar dosage is also used in patients experiencing delayed graft function. Other adverse events along with their treatment details are explained in Table 2. There are also miscellaneous medicines usually used after transplantation which are listed in Table 4.

Analysis

The model was constructed using Microsoft Excel[®] 2010. The total cost included cost of initial hospitalization for transplantation, cost of immunosuppressive agents, cost of adverse events and miscellaneous medicines. Total cost was expressed in both Iranian Rials (IRR) and US dollars (\$USD). According to the official exchange price in

the study year, one USD was equal to 12,260 IRR.

Monte-Carlo simulation

In order to test the reliability of each individual AE probability used as the model input, a Monte-Carlo model was run, to simulate a random sampling of 2,200 patients out of total population.

The idea of the Monte-Carlo analysis is the generation of large number of (*e.g.* 100-1000) synthetic datasets that are similar to the experimental dataset, but with different distributed noise. Each of these new datasets is analyzed, and the distributions are stored. The resulting set of distributions can then be studied, point by point, and the mean and probability contours could be calculated (18, 19).

Results

In the present study, treatment cost of renal transplantation was calculated for a 1-year time horizon (first year) from the perspective of insurance organizations.

According to the model, almost 2,200 patients with ESRD had their renal transplantation in the study year. The estimated expected

Table 5. Total treatment cost of rena	l transplantation therapy	for insurance organizations in	Iran (2011-2012).
---------------------------------------	---------------------------	--------------------------------	-------------------

Treatment Cost of RTT	Values (IRR)	Values (\$US)	
Initial hospitalization for Transplantation	85,800,000,000	6,998,369	
Immunosuppressive agents	39,571,037,000	3,227,654	
Treatment of adverse events	43,220,945,900	3,525,363	
Miscellaneous medicines	2,126,344,000	173,438	
Total Costs	170,718,326,900	13,924,823	
Total Cost/patient	77,599,240	6,329	




Figure 1. Total treatment cost components of renal transplantation therapy, Iran (2011-2012).

year1treatment cost of RTT with the current standard therapy strategy was almost 171 billion IRR (\$14,000,000) for insurance organizations, which was almost 78 million IRR (\$ 6,500) per patient. These figures included cost of initial hospitalization for transplantation (50% of total costs), immunosuppressive agents (23% of total costs) and cost of adverse events (26% of total costs) and miscellaneous drugs (1% of total costs) (Table 5, Figure 1).

Regarding Monte-Carlo simulation, in essence, the model allows building up a probability distribution function, and thus studying how much the noise of the data is translated into the distribution. In the current study, the best-fit distribution represents the <true> data well enough, so that the effects of noise on the simulated data and the real data are quite the same (18, 19).

According to Table 3, the average cost of AEs per patient calculated based on probabilities extracted from the literature was quite similar to the average cost of AEs per patient calculated by Monte Carlo model throughout several repeated simulations (19,600,000 IRR; \$1,600 vs. 19 – 20 million IRR ; \$1550- 1630). It shows that the probabilities are as much reliable as if came from a random sampling.

Discussion

At present, Iran has one of the most successful transplantation programs in the Middle East (6). In Iran, renal transplantation is grouped as a special disease which is paid by different organizations. MOH as the main sponsor along with health insurance organizations covers almost all medicines and medical services included in the standard guidelines approved to be used in RTT.

In order to improve quality of care in terms of patient and graft survival, policy makers of insurance organizations should always make choice between newly introduced drugs, which are quite expensive, and the current alternatives (5) that is exactly when economic and financial evaluations could play an essential role in making reimbursement decisions (20).

In the present study, treatment cost of renal transplantation during the first year was calculated to provide insurance policy makers with an estimation of current practice expenses and compare it with future financial consequences of newly proposed medicines have been applied to be added to their formulary (budget impact analysis) (21). Based on the results of this study, considering 17,000 patients receiving RTT, out of which about 2,200 patients had their renal transplantation operation during the study year, the estimated 1-year therapy cost of renal transplantation was almost 78 million IRR (\$ 6, 500) per patient from Mar. 2011 to Mar. 2012. More than half of this expense was related to the initial hospitalization for transplantation (Figure 1), highlighting the importance of improving preventive interventions such as using more potent and effective immunosuppressive agents to have fewer cases of graft failure and retransplantation.

Further to the present study, the first budget impact analysis has been conducted in Iran on applying mTOR inhibitors as immunosuppressive medication in replace to Ciclosporine (22).

Policy making recommendations

Renal transplantation therapy versus hemodialysis

According to the literature, in ESRD, costs of renal replacement therapy (RRT) by hemodialysis are far greater than cost of renal transplantation therapy (23, 24). According to the results of the present study, in Iran, only considering hospital-based hemodialysis tariff

Total cost components	Values (IRR)	Values (\$US)	
Dialysis	255,066,240,000	20,804,750	
Adjunct treatment	46,706,880,000	3,809,697	
Total Costs	301,773,120,000	24,614,447	
Total Cost per patient	137,169,600	11,188	

Table 6. Annual cost of dialysis in case all patients receive hemodialysis rather than renal transplantation, Iran (2011-2012).

and required important medications such as erythropoietin and calcitriol, without including any adverse event expenses, 1-year therapy cost per patient would be almost 137 million IRR (\$11,000), which is about 2 times greater than cost of RTT per patient (78 million IRR; \$6,500) (Table 6).

Considering financial, economic and qualityof-life advantages in low and middle income countries, transplantation is an attractive modality over hemodialysis (25).

Burden of chronic kidney disease (CKD) and End-stage Renal Disease (ESRD) in Iran.

Having introduced CKD and ESRD as public health problems, in 2004, Nafar et al. calculated disability adjusted life years (DALYs) for both conditions in Iran. According to their analysis, DALY for ESRD and CKD was calculated as almost 21,490 years and 1,124,164 years, respectively. It means that in Iran, more than 1 million healthy lives were lost every year due to CKD. Total DALY per 1000 population was calculated as 17.22 years, which was a considerably high value compared with other life threatening diseases such as cancers. Considering the fact that average age of the sample patient population was almost 46 years old and they were still grouped as young population, loss of productivity and decrease in active working population (as tax and insurance co- payers) are considered the most concerning issues caused by ESRD and CKD from economic point of view. Consequently, any preventive or therapy strategy which could decrease DALY or burden of ESRD and CKD in our society is strongly recommended and worth to be provided with satisfying financial resources. In this regard, screening tests to prevent ESRD as well as providing affordable RTT and maximizing patient and graft survival through providing effective immunosuppressive drugs are critical (3, 25).

Conclusion

Renal transplantation therapy is currently fully reimbursed in Iran. However, new expensive drugs improving patient and graft survival are increasingly introduced to physicians and patients and in terms of budget limitations, making decisions about their insurance coverage is quite challenging for policy makers. Thus, estimating the current budget spending on RTT would help them in making comparison between new and current therapy strategies and would increase efficiency in resource allocation as well as decreasing current quite high out-of-pocket expenditures.

Acknowledgments

The authors would like to thank Dr. Zahra Sahraee, Dr. Hossein Vatanpour, Dr. Hamid Reza Safikhani, Dr. Farshad Shirazi, Dr. Mehrdad Faizi, Dr. S. Abbas Tabatabaee, Dr. Ali Reza Shafaati, Dr. Faraz Mojab and Reza Mohammadzadeh for their contribution in this project.

References

- (1) Berthoux F, Jones E, Gellert R and Mendel S. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries. *Nephrol Dial Transplant* (1999) 14: 2332-2342.
- (2) Han F, Wu J, Huang H, Zhang X, He Q, Wang Y Wang S, Wang H and Chen J. Conversion from Cyclosporine to Sirolimus in Chronic Renal Allograft Dysfunction: A 4-Year Prospective Study. *Experiment. Clin. Transplantation* (2011) 9: 42-49.
- (3) Nafar M, Mousavi S, Mahdavi M, Pour-Reza-Gholi F, Firoozan A, Einollahi B, Lessan-Pezeshki ML, Asbaghi-Namini S and Farrokhi F. Burden of Chronic Kidney Disease in Iran: A Screening Program is of Essential Need. *Iran. J. Kidney Dis.* (2008) 2: 183-192. Nafar M, Alipour B, Ahmadpour P, Pour-Reza-Gholi,

- (4) F, Samadian F, Samavat S and Farhangi S. Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation. *Iran. J. Kidney Dis.* (2012) 6: 300-306.
- Tayebi Khosroshahi H. Short history about renal
 (5) transplantation program in Iran and the world: Special focus on world kidney day. *J. Nephropathology*. (2012) 1:5-10.
- Einollahi B. Kidney Transplantation in Iran. *Iran. J.* (6) *Med. Sci.* (2010) 35: 1-8.
- Hajizadeh M and Nghiem H. Out-of-pocket (7) expenditures for hospital care in Iran: who is at risk of
- (7) expenditures for hospital care in Iran: who is at risk of incurring catastrophic payments? *Int. J. Health Care. Finance Econ.* (2011) 11: 267-285.
 Mehrdad R. Health System in Iran. *JMAJ.* (2009) 52:
- (8) 69-73. Mahdavi-Mazdeh M, HeidaryRouchi A, Norouzi
- (9) S, Aghighi M, Rajolani H and Ahrabi S. Renal Replacement Therapy in Iran. *J. Urology* (2007) 4: 66-70.

Fahimi F, Baniasadi S, Mortazavi S.A, Dehghan Hanie

- (10) and Zarghi A. Physical and Chemical Stability of Mycophenolate Mofetil (MMF) Suspension Prepared at the Hospital. *Iran. J. Pharm. Res.* (2012) 11: 171-175.
 - Ghadiani MH, Peyrovi S, Mousavinasab S and
- (11) Jalalzadeh M. Delayed Graft Function, Allograft and Patient Survival in Kidney Transplantation. Arab. J. Nephrol. Transplantation (2012) 5: 19- 24. Ramezani M, Einollahi B, Ahmadzad-Asl M, Nafar M,
- (12) Pourfarziani V, Samadpour A, Moradi M, Alghasi M, Chalian H and Davoudi F. Hyperlipidemia after Renal Transplantation and its relation to graft and patient survival . *Transplantation Proceedings* (2007) 39: 1044-1047.

Buchler M, Caillard S, Barbier S, Thervet E, Toupance

(13) O and Lemeur Y. Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin MycophenolateMofetil and a 6-Month Course of Steroids. *American J. Transplantation* (2007) 7: 2522-2531.

Cravedi P, Ruggenenti P and Remuzzi G. Sirolimus for

 (14) calcineurin inhibitors in organ transplantation: contra. *Kidney International* (2010) 78: 1068-1074.
 Groth CG, Backman L, Morales JM, Calne R and

- (15) Kreis H. Sirolimus (Rapamycin)-Based Therapy in Human Renal Transplantation: Similar Efficacy and Different Toxicity Compared with Cyclosporine. *Transplantation*. (1999) 67: 1036-1042.
- Saadat A, Einollahi B, Ahmadzad-Asl M, Moradi (16) M, Nafar M and Pourfarziani V. Posttransplantation Lymphoproliferative Disorders in Renal Transplan Recipients: Report of over 20 years of experience. *Transplantation proceedings* (2007) 39: 1071-1073. Pourfarziani V, Nourbala M, Azizabadi M, Moghani
- (17) Lankarani M and Assari S. Costs and Length of Hospitalizations Following Kidney Transplantation. *Iran. J. Kidney Dis.* (2009) 3: 103-108.
- Bankes J, Carson JS, Nelson Bl and Nicol DM. (18) Discrete-Event System Simulation. 5th ed. Pearson Education, New Jersey (2009).
- Binder and Heermann DW. Monte Carlo Simulation in (19) Statistical Physics. 4th ed. Springer Series.
- Davari M. Pharmacoeconomics; an Appropriate Tool (20) for Policy Makers or Just a New Field of Research in
- Iran? *Iran. J. Pharm. Res.* (2012) 11: 1-2. Mauskopf J, Sullivan S, Annemans L, Caro J, Mullins
- (21) C, Nuijten M, Orlewska E, Watkins J and Trueman P. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices: Budget Impact Analysis. *Value in health* (2007) 10: 336- 347.

Foroutan N, Rasekh HR, Salamzadeh J, Jamshidi HR

- (22) and Nafar M. Budget Impact Analysis of Conversion from Cyclosporine to Sirolimus (Rapamune ®) in Renal Transplantation Therapy. *Clinicoecon Outcomes Res.* (2013)18: 545-553.
- Perović S and Janković S. Renal transplantation vs. (23) hemodialysis: cost-effectiveness analysis. *Vojnosanit Pregl.* (2009) 66: 639-644.
- Karlberg I and Nyberg G. Cost-Effectiveness Studies (24) of Renal Transplantation. *Int. J. Technol. Assessment in Health Care* (1995) 11: 611-622.
 - White SL, Chadban SJ, Chapman JR and Cass A.
- (25) How can we achieve global equity in provision of renal replacement therapy? Bulletin of the World Health Organization [Internet]. Accessed Apr 26 2013. Available from: URL: http://www.who.int/bulletin/ volumes/86/3/07-041715/en.

This article is available online at http://www.ijpr.ir